argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus
Go back to argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus| (NASDAQ: ARGX) | Delayed: 990.32 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $990.32 | 52 Week High | $ | |||
| Open | $990.32 | 52 Week Low | $ | |||
| Day High | $990.32 | P/E | N/A | |||
| Day Low | $990.32 | EPS | $ | |||
| Volume | 15 | |||||
| (NASDAQ: ARGX) | Delayed: 990.32 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $990.32 | 52 Week High | $ | |||
| Open | $990.32 | 52 Week Low | $ | |||
| Day High | $990.32 | P/E | N/A | |||
| Day Low | $990.32 | EPS | $ | |||
| Volume | 15 | |||||

